Quantcast

Latest Proteasome Stories

2010-09-08 14:33:42

Discovery reveals a natural mechanism for getting rid of excess amyloid Chemists at the University of California, San Diego, have identified how a protein that accumulates in the brains of people with Alzheimer's disease interferes with the ability of cells to get rid of debris. They also found a natural mechanism by which this protein, amyloid beta, itself may be discarded. Plaques of amyloid are a hallmark of the ailment, but no one is sure exactly how they contribute to catastrophic loss...

2010-09-08 02:00:00

EMERYVILLE, Calif., Sept. 8 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it has entered into an exclusive agreement with Ono Pharmaceutical Co., Ltd. to develop and commercialize two compounds from Onyx's proteasome inhibitor development program, carfilzomib and ONX 0912. Under the terms of the agreement, Ono has exclusive rights to develop and commercialize both compounds for all oncology indications in Japan. Onyx retains commercialization...

2010-09-07 15:00:00

EMERYVILLE, Calif., Sept. 7 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the Morgan Stanley Global Healthcare Conference on Monday, September 13, 2010 at 10:20 a.m. Eastern Time (7:20 a.m. Pacific Time). Interested parties may access a live webcast of the presentation on our website at: http://www.onyx-pharm.com/view.cfm/32/Event-Calendar It is recommended that listeners log on 15 minutes early in order to register and download any...

2010-08-17 17:19:21

Findings show that rather than a straightforward "off-on" switch, the MDM2 oncogene is controlled by a more complicated "dimmer switch" that is sensitive to its changing environment Researchers at Beth Israel Deaconess Medical Center (BIDMC) have uncovered the genes that regulate MDM2, an oncogene that, in turn, regulates the tumor suppressor protein p53. But instead of an on-off switch for MDM2, the team found what looks like a dimmer switch, suggesting a more complicated signaling pathway...

2010-08-03 15:00:00

EMERYVILLE, Calif., Aug. 3 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the Canaccord Genuity 30th Annual Growth Conference on Tuesday, August 10, 2010 at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time). Interested parties may access a live webcast of the presentation on our website at: http://www.onyx-pharm.com/view.cfm/32/Event-Calendar It is recommended that listeners log on 15 minutes early in order to register and...

2010-07-12 14:11:11

Findings by the John Theurer Cancer Center may lead to more targeted clinical trials and therapies A new study by researchers from the John Theurer Cancer Center at Hackensack University Medical Center sheds light on how bortezomib (VELCADE®), the first in a new class of cancer drugs known as proteasome inhibitors, works in mantle cell lymphoma. The study also provides preliminary evidence for which patients might benefit most from bortezomib. Additionally, researchers...

2010-06-22 07:00:00

SAN DIEGO, June 22 /PRNewswire/ -- Nereus Pharmaceuticals, Inc., a pioneer in drug discovery and development from marine microbial sources, announced completion of enrollment in the randomized Phase 2 ADVANCE study evaluating its tumor selective vascular disrupting agent (VDA), plinabulin (NPI-2358), in patients with non-small cell lung cancer (NSCLC) who have failed treatment with chemotherapy. Approximately 170 patients were enrolled in this international clinical trial. The study is...

2010-06-22 02:13:54

Pulmonary arterial hypertension (PAH) is a progressive disease, marked by shortness of breath and fatigue which can be fatal if untreated. Increased pressure in the pulmonary artery and its branches is associated with dysfunctional growth control of endothelial and smooth muscle cells leading to excessive thickening of the blood vessel wall, obliteration of the lumen and right heart failure. BMP (bone morphogenetic protein) receptors play an important role in preventing excess growth of...

2010-06-08 15:00:00

EMERYVILLE, Calif., June 8 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at Goldman Sachs 31st Annual Global Healthcare Conference on Tuesday, June 15, 2010 at 4:55 p.m. Eastern Time (1:55 p.m. Pacific Time). Interested parties may access a live webcast of the presentation on our website at: http://www.onyx-pharm.com/view.cfm/32/Event-Calendar It is recommended that listeners log on 15 minutes early in order to register and...

2010-06-01 08:00:00

EMERYVILLE, Calif., June 1 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the initiation of a Phase 1 study of ONX 0912, an oral proteasome inhibitor, in patients with advanced refractory or recurrent solid tumors. "Based on insights gained from our ongoing carfilzomib development program and ONX 0912's favorable preclinical profile - anti-tumor activity, safety and biodistribution - we believe ONX 0912 may have the potential to expand the use of...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related